NCT01956253No Longer Available不适用
Single Subject Neratinib in Bladder Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesBreast CancerNCT01494662Dana-Farber Cancer Institute140
已完成
不适用
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation StudyBladder CancerNCT03715660Mansoura University198
尚未招募
1 期
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant AscitesGynecologic CancerNCT06415500Anhui Provincial Hospital9
进行中（未招募）
2 期
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsLocally Advanced Bladder Urothelial CarcinomaMetastatic Transitional Cell CarcinomaMetastatic Urothelial CarcinomaRecurrent Bladder CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7NCT03047213National Cancer Institute (NCI)17
已完成
2 期
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerBreast NeoplasmsNCT01670877Washington University School of Medicine56